0.85 USD
▼-0.04-4.46%
盘后 0.85 -0.33%
2026-11-20
市值
$66.34M
市盈率
—
EPS
-0.54
股息率
—
52 周区间
0.71 – 3.31
成交量
520.72K
Beta
1.56
目标价
5.14
52W 低 0.7152W 高 3.31
价格走势
公司简介
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CR...